Yun Qin

Title: Innovations in Cancer Treatment by Inventor Yun Qin

Introduction

Yun Qin is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of oncology through his innovative research and development of pharmaceutical compositions aimed at treating tumors and cancers. His work focuses on the use of recombinant oncolytic adenoviruses, which have the potential to revolutionize cancer therapies.

Latest Patents

Yun Qin holds a patent for an isolated recombinant oncolytic adenovirus, along with pharmaceutical compositions and their uses for drug treatment of tumors and/or cancers. The patent describes a selectively replicating oncolytic adenovirus that integrates a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. This innovative approach allows the virus to replicate more effectively in tumor cells compared to normal primary cells. The expressed shPDL1 significantly reduces the level of PDL1 protein in tumor cells, enhancing the oncolytic killing effect of the virus and stimulating an anti-tumor immune response.

Career Highlights

Yun Qin is associated with Hangzhou Converd Co., Ltd., where he continues to advance his research in cancer treatment. His work has garnered attention for its potential to improve therapeutic outcomes for patients suffering from various forms of cancer.

Collaborations

Yun Qin collaborates with notable colleagues, including Jipo Sheng and Jin Fu, who contribute to his research efforts and the development of innovative cancer therapies.

Conclusion

Yun Qin's groundbreaking work in the field of oncology exemplifies the potential of innovative treatments for cancer. His patented technology represents a significant advancement in the fight against tumors and cancers, showcasing the importance of research and collaboration in developing effective therapies.